Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain

Neuroscience

• Aripiprazole 100%
• Dopamine Release 90%
• Prefrontal Cortex 90%
• Nucleus Accumbens 50%
• Hippocampus 50%
• Atypical Antipsychotic 30%
• Acetylcholine Release 30%
• Haloperidol 20%
• Receptor Antagonist 20%
• 5-HT1A Receptor 20%
• Receptor Partial Agonist 20%
• Clozapine 10%
• Antipsychotic 10%
• Negative Syndrome 10%
• 5-HT2A Receptor 10%
• Typical Antipsychotic 10%
• Dopamine Receptor D2 10%
• Brain 10%
• Cognition 10%
• Cognitive Function 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Aripiprazole 100%
• Dopamine 90%
• Atypical Antipsychotics 30%
• Acetylcholine 30%
• Haloperidol 20%
• N [2 [4 (2 Methoxyphenyl) 1 Piperazinyl]ethyl] N (2 Pyridyl)cyclohexanecarboxamide 20%
• Partial Agonist 20%
• Rat 20%
• Clozapine 10%
• Serotonin 2A Antagonist 10%
• Serotonin 1A Antagonist 10%
• Negative Syndrome 10%
• Dopamine Receptor D2 10%

INIS

• dopamine 100%
• drugs 50%
• hippocampus 50%
• nuclei 50%
• receptors 40%
• acetylcholine 30%
• rats 20%
• doses 20%
• brain 10%
• symptoms 10%